Replimune Group (NASDAQ:REPL) Receives New Coverage from Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of Replimune Group (NASDAQ:REPL) in a research note published on Tuesday, Benzinga reports. The firm issued a buy rating and a $17.00 price objective on the stock.

A number of other analysts have also recently weighed in on REPL. Barclays upped their price target on Replimune Group from $13.00 to $17.00 and gave the company an overweight rating in a research report on Friday, June 7th. JPMorgan Chase & Co. lowered their price target on Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research report on Tuesday, August 13th. Wedbush reiterated an outperform rating and issued a $16.00 price target on shares of Replimune Group in a research report on Thursday, June 6th. Finally, HC Wainwright increased their target price on Replimune Group from $12.00 to $17.00 and gave the stock a buy rating in a report on Friday, June 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average target price of $16.20.

Replimune Group Stock Performance

REPL opened at $9.99 on Tuesday. The stock has a market cap of $613.54 million, a PE ratio of -3.08 and a beta of 1.25. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a 1 year low of $4.92 and a 1 year high of $21.32. The stock’s 50 day simple moving average is $9.58 and its 200-day simple moving average is $8.12.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Sell-side analysts forecast that Replimune Group will post -3.08 EPS for the current year.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the transaction, the insider now owns 117,131 shares of the company’s stock, valued at $878,482.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 15,881 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $7.50, for a total value of $119,107.50. Following the transaction, the insider now directly owns 117,131 shares in the company, valued at approximately $878,482.50. The disclosure for this sale can be found here. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in Replimune Group by 236.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the period. Nisa Investment Advisors LLC lifted its stake in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new position in Replimune Group in the second quarter valued at about $57,000. Quest Partners LLC acquired a new position in Replimune Group in the fourth quarter valued at about $76,000. Finally, Diversified Trust Co acquired a new position in Replimune Group in the first quarter valued at about $94,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.